A Randomized, Double-Blind, Pilot Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, to Investigate Peripheral Blood and Mucosal Mononuclear Cell Phenotype and Cytokine Responses in Patients With Crohn's Disease.
Latest Information Update: 03 Oct 2021
At a glance
- Drugs Apilimod dimesylate (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Sponsors Synta Pharmaceuticals
- 07 Jan 2010 New trial record
- 07 Jan 2010 New trial record